Role of neoadjuvant therapy for esophageal adenocarcinoma.
This article examines the role of neoadjuvant therapy in the treatment of locally advanced esophageal adenocarcinoma. Recent studies have demonstrated that pre- or perioperative chemotherapy is associated with improved survival. Neoadjuvant chemoradiotherapy continues to be investigated but is associated with several advantages over neoadjuvant chemotherapy alone. Primary chemoradiotherapy is the accepted standard of care for medically inoperable patients, whereas adjuvant chemoradiotherapy may be considered for patients who undergo primary resection of lower esophageal/gastroesophageal junction tumors. Future directions include the investigation of newer chemotherapy regimens, the addition of targeted therapies, and the use of position emission tomography to provide an early assessment of response.
Ku
Geoffrey Y
GY
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY 10065, USA.
Ilson
David H
DH
D000230:Adenocarcinoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016629:Esophagectomy; D055317:Evidence-Based Practice; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011182:Postoperative Care; D011300:Preoperative Care; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D016896:Treatment Outcome
D002945:Cisplatin